ATLANTA--(BUSINESS WIRE)--Tom Knight, founder of Optinosis, a maker of AI-enabled tools for early disease detection, will lead the organization as CEO. Knight will guide the early stage startup as it builds healthcare solutions to detect diseases like cancer earlier, with a goal of improving outcomes and lowering overall cost of care for patients and health plans..

亚特兰大——（商业新闻短讯）——Optinosis的创始人汤姆·奈特（TomKnight）将领导该组织担任首席执行官，Optinosis是一家人工智能早期疾病检测工具的制造商。Knight将指导这家早期创业公司建立医疗保健解决方案，以尽早发现癌症等疾病，目标是改善结果，降低患者护理和健康计划的总体成本。。

Knight, who holds a master's degree in engineering and an MBA from the Massachusetts Institute of Technology (MIT), most recently founded and led Invistics, a U.S.-based provider of AI-enabled drug diversion detection software, which was acquired by Wolters Kluwer in 2023. His career has focused on leveraging AI to solve challenges across sectors, including healthcare, manufacturing and supply chain..

奈特拥有麻省理工学院（MIT）的工程学硕士学位和MBA学位，最近成立并领导了Invistics，Invistics是一家美国的人工智能药物转移检测软件提供商，该软件于2023年被Wolters Kluwer收购。他的职业生涯专注于利用人工智能来解决跨部门的挑战，包括医疗保健、制造业和供应链。。

“AI and preventative care are poised to radically disrupt the healthcare industry, but it will take the right tools and leadership to build effective solutions that align all stakeholders,” said Sig Mosley, chairman of Optinosis’ board and serial technology investor. “Tom has a long history of creating the right teams and strategically scaling operations to solve some of healthcare’s most pressing challenges, and I have no doubt he’ll lead Optinosis with the same passion and expertise he’s applied throughout his career.”.

Optinosis董事会主席兼系列技术投资者西格·莫斯利（Sig Mosley）表示：“人工智能和预防保健准备从根本上扰乱医疗保健行业，但需要正确的工具和领导才能构建有效的解决方案，使所有利益相关者保持一致。”。“Tom在创建合适的团队和战略性扩展运营方面有着悠久的历史，以解决医疗保健领域一些最紧迫的挑战，我相信他将以他在整个职业生涯中所应用的激情和专业知识领导Optinosis。”。

The National Institutes of Health (NIH) reports that nearly four in ten Americans will be diagnosed with cancer in their lifetimes. Optinosis will help providers detect common cancers earlier by using AI to analyze existing patient health records. This early detection will give patients stronger prognoses while lowering the overall cost of cancer care for Medicare Advantage and other health plans..

美国国立卫生研究院（National Institutes of Health，NIH）报告称，近十分之四的美国人在一生中会被诊断出患有癌症。Optinosis将通过使用AI分析现有患者健康记录，帮助提供者更早地发现常见癌症。这种早期发现将为患者提供更强的预后，同时降低医疗保险优势和其他健康计划的癌症护理总体成本。。

“Cancer is the second-highest cause of death in the United States and is a major expenditure across our healthcare ecosystem. Early detection and treatment is literally a matter of life and death,” Knight said. “Optinosis can use existing data within a healthcare record to more quickly determine if a patient is at-risk.

奈特说：“癌症是美国第二大死亡原因，是整个医疗保健生态系统的主要支出。早期发现和治疗实际上是一个生死攸关的问题。”。“Optinosis可以使用医疗记录中的现有数据来更快地确定患者是否处于危险之中。

Our tools will help countless Americans live better, longer lives while alleviating financial pressures for Medicare Advantage and other health plans as they pay increasingly more to treat cancers in our country.”.

我们的工具将帮助无数美国人过上更好、更长的生活，同时缓解医疗保险优势和其他健康计划的财务压力，因为他们在我国治疗癌症的费用越来越高。”。

About Optinosis™

Optinosis™

Optinosis builds AI-enabled healthcare solutions that detect diseases earlier and reduce the cost of patient care. Leveraging the power of AI, Optinosis uncovers new insights and risk factors within existing patient health records and other data sources. Optinosis solutions can more quickly and accurately detect potential life-threatening diseases, like cancers, to improve patient outcomes, while simultaneously reducing costs for Medicare Advantage health plans.

Optinosis构建了支持人工智能的医疗保健解决方案，可以更早地发现疾病并降低患者护理成本。利用人工智能的强大功能，Optinosis在现有患者健康记录和其他数据源中发现了新的见解和风险因素。Optinosis解决方案可以更快速准确地检测潜在的威胁生命的疾病，如癌症，以改善患者的预后，同时降低Medicare Advantage健康计划的成本。

Learn more about Optinosis or contact info@optinosis.com..

了解有关Optinosis或contact的更多信息info@optinosis.com..